In the evening of 24^th, Aug., Joincare Pharmaceutical Group Industry Co., Ltd (Joincare) has released the public notification that the company gained the ‘Drug Production License’ (DPL). Until now, the two major combination medicinal products developed by Joincare, Compound Ipratropium Bromide Solution for Inhalation and Levosalbutamol Hydrochloride Nebuliser Solution, have begun to be manufactured.

Recently, Joincare has received the DPL issued by Medical Products Administration of Guangdong Province. The license allowed the company to be the Marketing Authorization Holder of the two combination medicinal products, and also permitted its two subsidiaries, Shenzhen Taitai Biotechnology Co., Ltd. and Shenzhen Haibin Pharmaceutical Co., Ltd., to be the entrusted producers of the medicinal products mentioned above.

According to the report, under the Law of Medical Administration, Medical Products Administration can issue the DPL after the quality inspection on facility, equipment, product quality, inspecting device and regulation on quality insurance.

The data open to the public has shown that, in the April and September of 2019, Joincare has registered the two major combination medicinal products. It is the block buster at the moment, when the medical products have been sold on the market.

DPL means that inhale medicine developed by Joincare has been recognized by the nation and the society. This facilitate the company to integrate itself, allocate production resources, improve production capacity, lower cost, and amend the quality regulation on every life stage of medical products.

As a inclusive medical company with the ability to research, product, sale and serve, Joincare unyieldingly research and produce the medicine for respiratory system. After years of development, the company has built a clear program for product research, and its inhalation is starting to receive benefits. Apart from the two medical products above, Joincare is researching many other inhalations shown great potentials. For example, in the July of this year, Budesonide Suspension for Inhalation was sold on the market. This inhalation provided more than 100 million patients with a safer, better option of medical products.

Some experts have analyzed that, after more ground-breaking works have been made, the future of respiratory department and the market of inhalations will be prosperous. Joincare has been recognized as one of the leading companies by the industry for its ability to set up strategy ahead, research fast, and act effectively.

Accordingly, Joincare has a rather bright future for its advantages on the development of technologies and products.